Clinical Trial Update: An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 active-treatment trial of SRK-015 in spinal muscular atrophy (types 2 and 3) with results posted in November 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• SRK-015

Snippet

Sponsor: Scholar Rock, Inc. | Conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 2 | Status: COMPLETED | Results posted: 2022-11-17